Lung Cancer (PACIFIC-4 / RTOG-3515)

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of Patients with Stage I/II Non Small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Location: SIMR (Sacramento/Valley Area)

Please contact: Isabel Rodrigues-Fong (RodrigI@sutterhealth.org) or Kirsten Babski (BabskiK@sutterhealth.org)

Principal Investigator

Christopher Jones, MD

Co-Investigator(s)

Vijay Suhag, M.D., Anthony T Pu, Radiation Oncologist, Charlotte D Kubicky, Radiation Oncologist, Hubert Y Pan, Radiation Oncologist, Sivakumar Reddy, M.D., Deepti Behl, MD, Carlin R Hauck, Radiation Oncologist 

Recruitment Status

Active, Recruiting

Funder

Astra Zeneca

Start Date

October 22, 2020